Policy & Regulation
Acadia Pharmaceuticals announces receipt of FDA Fast Track designation for remlifanserin to treat Alzheimer's disease psychosis
20 July 2026 - Acadia Pharmaceuticals (Nasdaq: ACAD), a developer of treatments for neurological and rare diseases, revealed on Monday that it has received U.S. Food and Drug Administration Fast Track...
Almirall advances Ebglyss paediatric regulatory filing in Europe
20 July 2026 - Spanish pharmaceutical company Almirall S.A. (BME:ALM) said on Monday that the European Medicines Agency has accepted its submission to extend the Marketing Authorisation Application fo...
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/...
GSK seeks European approval for single-dose Bexsero booster in older children and adults
20 July 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) reported on Monday that the European Medicines Agency has accepted its submission to update the Bexsero label to include a singl...
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
20 July 2026 - Evaxion A/S, a Denmark-based, clinical-stage TechBio company developing novel vaccines with its AI-Immunology platform, said on Friday that it will present three-year clinical efficacy ...
Ananda Pharma doses first patient in MRX1 clinical trial of patients with chemotherapy induced peripheral neuropathy
20 July 2026 - UK biopharmaceutical company Ananda Pharma Limited announced on Friday that the first patient taking part in the ACTiON clinical trial investigating the efficacy of MRX1, Ananda's ...